Presentation

Cantargia is a Swedish biotechnology company that develops antibody-based treatments for cancers and autoimmune & inflammatory diseases. The lead asset nadunolimab (CAN04) targets IL-1RAP and induces antibody-dependent cellular cytotoxicity. Nadunolimab is being studied in 5 clinical trials in different cancer indications and combination therapies. Cantargia also has a preclinical asset CAN10 for autoimmune & inflammatory diseases.

Recent highlights
In January, Cantagaria announced that nadunolimab in pancreatic cancer was advanced to Ph2/3 through collaboration with Pancreatic Cancer Action Network (PanCAN). In June, several positive interim results of nadunolimab were announced: Ph2a trial in NSCLC treated in combination with gemcitabine and cisplatin showed an overall response rate well above historical data of chemotherapy alone, with an acceptable safety profile manageable by G-CSF; Ph1/2a in first-line pancreatic cancer combined with gemcitabine and nab-paclitaxel showed superior overall survival, 1-year survival and iPFS to historical data of chemotherapy alone with similar safety profile; Ph1b in solid tumours combined with Pembrolizumab showed positive safety results, disease control for at least 30 wks in 6 of 15 patients, and biomarker profile with lower CRP and IL-6.

Outlook
Cantargia will advance nadunolimab to late-stage clinical stage through collaboration with PanCAN in a Ph2/3 pancreatic cancer trial, and a non-squamous NSCLC randomized trial, expected to start in 2023. The company also aims to complete final preparations for the start of the first clinical trial of CAN10 in 2023.